FDA Advisers Recommend JN.1-Based COVID Vaccine for Fall

New formula aims to improve protection against evolving variants as manufacturers prepare for autumn rollout.

FDA panel unanimously supports targeting JN.1 variant for 2024-25 COVID vaccines.
JN.1-based vaccines shown to neutralize newer subvariants like KP.2 more effectively.
Pfizer, Moderna, and Novavax ready to supply updated vaccines by late summer.
Current COVID-19 cases and hospitalizations remain low, but experts anticipate future surges.
CDC data reveals low vaccination rates among adults and nursing home residents.